BRAF and neoplasm: To further assess the specific contribution of EDNRB and EDNRA signalling to the response to BRAF inhibition in vivo, we treated mice bearing A375 tumours either with BQ788, which has a 1,000‐fold higher affinity for EDNRB than EDNRA (Okada & Nishikibe, 2002) or with macitentan with an approximately 800‐fold higher affinity for EDNRA than EDNRB (Boss et al, 2016).